Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Atai Beckley Inc.NASDAQ: ATAI

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 360.76M shares rose 83.5% year over year, ahead of the +66.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +83.5% holds above the trailing-twelve-month pace of +66.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
360.76M+0.9% QoQ
Last fiscal yearDec 2025
226.53M+41.4% YoY
LTMJun 2026
289.46M+66.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+83.5%——
1 year+41.4%——
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
226.53M USD
Year-over-year change
+41.4%
4-year CAGR
+9.0%

Weighted Avg Shares vs competitors

How ATAI compares with its peers on the latest reported figures

  • ATAI's LTM Jun 2026 weighted avg shares of 289.46M shares is the highest of the 11 companies compared; the peer median is 89.57M shares.
  • Its year-over-year change of +66.9% is the highest of 11, against a peer median of +18.9%.
  • Over three fiscal years its annual growth of +13.3% compares with a peer median of +13.9%.
ATAI Competitors Peer median
Weighted Avg Shares for ATAI and competitors
Company Period LTM YoY 3-year CAGR
ATAIAtai Beckley Inc.LTM Jun 2026289.46M +66.9%+13.3%
SANASana Biotechnology, Inc.LTM Mar 2026257.25M +9.0%+10.4%
RLAYRelay Therapeutics, Inc.LTM Jun 2026181.67M +12.1%+15.2%
IMTXImmatics N.V.LTM Mar 2026125.95M +14.7%+22.1%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026108.82M +29.3%+12.4%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
ELVNEnliven Therapeutics, Inc.LTM Sep 202665.9M +23.1%+108.5%
DNTHDianthus Therapeutics, Inc.LTM Jun 202644.91M +27.5%+116.1%
NKTRNektar TherapeuticsLTM Jun 202623.04M +64.4%+10.6%
INBXInhibrx Biosciences, Inc.LTM Mar 202615.5M +3.6%-27.2%
Peer median (excluding ATAI) 89.57M+18.9%+13.9%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.38M233K314K308K4.09M
Cost of Revenue47K168K319K473K1.01M
Gross Profit20.33M65K(5K)(165K)3.08M
Gross Margin99.8%27.9%-1.6%-53.6%75.3%
Research & Development47.91M74.15M61.88M54.98M53.06M
Selling, General & Admin92.75M70.35M63.58M47.54M49.78M
Operating Expenses140.65M144.5M125.47M102.53M102.84M
Depreciation & Amortization47K168K319K473K1.01M
EBITDA(178.19M)(150.1M)(39.9M)(147.33M)(657.68M)
EBITDA Margin-874.5%-64419.3%-12708.3%-47835.4%-16084.0%
Operating Income(120.33M)(144.43M)(125.47M)(102.69M)(99.76M)
Operating Margin-590.5%-61987.1%-39958.9%-33341.2%-2439.7%
Interest Income205K548K1.85M778K1.48M
Interest Expense0923K2.66M3.12M1.16M
Other Income / Expenses(57.91M)(6.76M)82.59M(48.24M)(560.09M)
Income Before Tax(178.23M)(151.19M)(42.88M)(150.93M)(659.85M)
Pre-Tax Margin-874.7%-64887.6%-13655.7%-49003.2%-16137.2%
Income Tax Expense(3.99M)6.23M1.02M(881K)298K
Net Income(167.81M)(152.39M)(40.22M)(149.27M)(660.05M)
Net Margin-823.6%-65401.3%-12810.2%-48464.0%-16142.0%
EPS (Basic)(1.04)(0.98)(0.25)(0.93)(2.91)
EPS (Diluted)(1.04)(0.98)(0.25)(0.93)(2.91)
Weighted Avg Shares160.68M155.72M158.83M160.16M226.53M
Weighted Avg Shares (Diluted)160.68M155.72M158.83M160.16M226.53M

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.